Meridian Bioscience (VIVO) Tops Q4 EPS by 4c, Revenue Beat; Offers FY19 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P 500, Dow futures muted ahead of jobs data; chips, software stocks rise
- Oil prices drop as investors weigh potential Hormuz deal between Iran, Gulf states
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Why a solid NFP report could spark a stock selloff, according to JPMorgan
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate, and Provides Fiscal 2019 Guidance
November 8, 2018 7:30 AM ESTCINCINNATI, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2018.
Business Highlights:
Completed consolidation of separately-run businesses into two integrated global business unitsStreamlined organization to build a stronger, more efficient and sustainable management structureEntered into a strategic collaboration with DiaSorin to sell Helicobacter Pylori testsLaunched new branding strategyReleased fiscal 2019 guidance of per share diluted earnings between $0.74 and $0.76 on net revenue growth of 2%-4% and operating margin of... More